RS61544B1 - Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja - Google Patents

Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja

Info

Publication number
RS61544B1
RS61544B1 RS20210286A RSP20210286A RS61544B1 RS 61544 B1 RS61544 B1 RS 61544B1 RS 20210286 A RS20210286 A RS 20210286A RS P20210286 A RSP20210286 A RS P20210286A RS 61544 B1 RS61544 B1 RS 61544B1
Authority
RS
Serbia
Prior art keywords
difluoropropionamide
polymorphs
derivative
pharmaceutical compositions
certain conditions
Prior art date
Application number
RS20210286A
Other languages
English (en)
Inventor
Eric Anderson
Andrea Decker
Xiaofeng Liu
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of RS61544B1 publication Critical patent/RS61544B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
RS20210286A 2012-04-27 2013-04-24 Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja RS61544B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261687669P 2012-04-27 2012-04-27
US201361775288P 2013-03-08 2013-03-08
US201361780444P 2013-03-13 2013-03-13
EP17175885.7A EP3444261B1 (en) 2012-04-27 2013-04-24 2,2-difluoropropionamide derivative of bardoxolone methyl, pharmaceutical compositions and polymorphs thereof for use in treating certain conditions

Publications (1)

Publication Number Publication Date
RS61544B1 true RS61544B1 (sr) 2021-04-29

Family

ID=49483867

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20170770A RS56154B1 (sr) 2012-04-27 2013-04-24 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
RS20210286A RS61544B1 (sr) 2012-04-27 2013-04-24 Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20170770A RS56154B1 (sr) 2012-04-27 2013-04-24 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu

Country Status (37)

Country Link
US (4) US8993640B2 (sr)
EP (2) EP2841445B1 (sr)
JP (2) JP6410710B2 (sr)
KR (1) KR102101774B1 (sr)
CN (1) CN104395332B (sr)
AR (1) AR092823A1 (sr)
AU (1) AU2013251602B2 (sr)
BR (1) BR112014026640B1 (sr)
CA (1) CA2869783C (sr)
CL (1) CL2014002886A1 (sr)
CO (1) CO7170182A2 (sr)
CY (2) CY1119333T1 (sr)
DK (2) DK2841445T3 (sr)
DO (1) DOP2014000236A (sr)
EA (1) EA030468B1 (sr)
ES (2) ES2634315T3 (sr)
FI (1) FIC20240012I1 (sr)
HK (2) HK1207085A1 (sr)
HR (1) HRP20171275T1 (sr)
HU (2) HUE035673T2 (sr)
IL (1) IL235275B (sr)
LT (2) LT3444261T (sr)
ME (1) ME02926B (sr)
MX (1) MX357060B (sr)
MY (1) MY172750A (sr)
NZ (1) NZ630222A (sr)
PE (1) PE20150160A1 (sr)
PL (2) PL3444261T3 (sr)
PT (2) PT3444261T (sr)
RS (2) RS56154B1 (sr)
SG (1) SG11201406868XA (sr)
SI (2) SI2841445T1 (sr)
TW (2) TWI623548B (sr)
UA (1) UA116209C2 (sr)
UY (1) UY34764A (sr)
WO (1) WO2013163344A1 (sr)
ZA (1) ZA201407326B (sr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
TWI453023B (zh) 2008-04-18 2014-09-21 Reata Pharmaceuticals Inc 抗氧化發炎調節劑：在ｃ－１７處具有胺基及其他修飾之齊墩果酸衍生物
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP2841445B1 (en) 2012-04-27 2017-06-14 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
TW201936625A (zh) * 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
WO2016070063A1 (en) 2014-10-31 2016-05-06 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CA3046183C (en) 2016-12-16 2024-02-20 Reata Pharmaceuticals, Inc. Pyrimidine tricyclic enone derivatives for inhibition of ror.gamma. and other uses
AU2019272960A1 (en) 2018-05-24 2020-12-10 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
PT3833662T (pt) 2018-08-20 2024-03-18 Janssen Pharmaceutica Nv Inibidores da interação proteína-proteína keap1-nrf2
EP3956342A4 (en) * 2019-02-15 2023-05-24 Triterpenoid Therapeutics, Inc. METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMOSOME AND/OR LON PROTEASE
CA3163745A1 (en) * 2019-12-03 2021-06-10 Baylor College Of Medicine Therapeutic compounds for methods of use in insulin resistance
WO2022126129A1 (en) 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
CN117015548A (zh) 2021-01-18 2023-11-07 里亚塔医药公司 合成的熊果酸衍生物和其使用方法
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) * 2021-06-23 2022-07-01 华中农业大学 一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
EP4349847A1 (en) 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5555153Y2 (sr) 1975-03-19 1980-12-20
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
MXPA01011613A (es) 1999-05-14 2003-10-14 Nereus Pharmaceuticals Inc Nuevos moduladores de interleucina-1 y factor-alfa de necrosis tumoral, sistesis de dichos moduladores y metodos de utilizar dichos moduladores.
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
WO2002026761A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP2005519913A (ja) 2002-01-18 2005-07-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 生物学的に活性な表面活性剤としてのトリテルペン第４アンモニウム塩
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
WO2006029221A2 (en) 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007112043A2 (en) 2006-03-23 2007-10-04 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008000070A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
PL2653873T3 (pl) 2007-02-08 2022-08-22 Biogen Idec Ma Inc. Kompozycje i zastosowania do leczenia stwardnienia rozsianego
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ME02751B (me) 2008-04-18 2018-01-20 Reata Pharmaceuticals Inc Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
TWI453023B (zh) 2008-04-18 2014-09-21 Reata Pharmaceuticals Inc 抗氧化發炎調節劑：在ｃ－１７處具有胺基及其他修飾之齊墩果酸衍生物
WO2009129545A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
EP2362770A4 (en) 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
CA2752048C (en) 2009-02-13 2014-11-25 Reata Pharmaceuticals, Inc. Delayed release, oral dosage compositions that contain amorphous cddo-me
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
CN102153613B (zh) 2011-02-28 2013-08-14 贵州省中国科学院天然产物化学重点实验室 夏枯草酸的制备方法和应用
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
CA2829618C (en) 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
EP2841445B1 (en) 2012-04-27 2017-06-14 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru) 2012-07-13 2013-07-20 Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CA2882417C (en) 2012-09-10 2021-04-20 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
JP2015527407A (ja) 2012-09-10 2015-09-17 アッヴィ・インコーポレイテッド グリチルレチン酸誘導体およびその使用方法
AU2012324029B2 (en) 2012-09-28 2015-05-14 Applied Pharmaceutical Science, Inc. Polymorphs of CDDO ethyl ester and uses thereof
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
TWI716341B (zh) 2013-08-23 2021-01-21 美商瑞塔醫藥有限責任公司 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
CA2936550C (en) 2014-01-24 2022-07-26 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CA3046183C (en) 2016-12-16 2024-02-20 Reata Pharmaceuticals, Inc. Pyrimidine tricyclic enone derivatives for inhibition of ror.gamma. and other uses

Also Published As

Publication number Publication date
CY1119333T1 (el) 2018-02-14
UY34764A (es) 2013-11-29
FIC20240012I1 (fi) 2024-04-18
EP3444261B1 (en) 2021-01-13
JP6410710B2 (ja) 2018-10-24
LT3444261T (lt) 2021-05-10
SI3444261T1 (sl) 2021-04-30
MX2014013076A (es) 2015-05-11
TW201726701A (zh) 2017-08-01
US20180009839A1 (en) 2018-01-11
DOP2014000236A (es) 2015-04-30
EP2841445B1 (en) 2017-06-14
WO2013163344A1 (en) 2013-10-31
DK3444261T3 (da) 2021-03-08
TW201348245A (zh) 2013-12-01
PL2841445T3 (pl) 2017-10-31
PE20150160A1 (es) 2015-02-19
US20130324599A1 (en) 2013-12-05
PT3444261T (pt) 2021-03-12
US20150259377A1 (en) 2015-09-17
BR112014026640B1 (pt) 2021-05-18
HK1207085A1 (en) 2016-01-22
CN104395332B (zh) 2017-01-18
US20210355156A1 (en) 2021-11-18
CA2869783C (en) 2022-06-21
HK1207086A1 (en) 2016-01-22
ES2634315T3 (es) 2017-09-27
PT2841445T (pt) 2017-09-01
RS56154B1 (sr) 2017-11-30
CY1124130T1 (el) 2022-05-27
HUE053113T2 (hu) 2021-06-28
MY172750A (en) 2019-12-11
US11078230B2 (en) 2021-08-03
CA2869783A1 (en) 2013-10-31
MX357060B (es) 2018-06-25
JP2015521166A (ja) 2015-07-27
CL2014002886A1 (es) 2015-02-06
KR102101774B1 (ko) 2020-04-20
SI2841445T1 (sl) 2017-12-29
PL3444261T3 (pl) 2021-07-19
AU2013251602A1 (en) 2014-10-23
US9701709B2 (en) 2017-07-11
AR092823A1 (es) 2015-05-06
IL235275B (en) 2018-03-29
JP6637136B2 (ja) 2020-01-29
JP2019011349A (ja) 2019-01-24
HUE035673T2 (en) 2018-05-28
EP2841445A1 (en) 2015-03-04
US8993640B2 (en) 2015-03-31
AU2013251602B2 (en) 2017-09-28
BR112014026640A2 (pt) 2017-07-18
NZ630222A (en) 2016-06-24
ZA201407326B (en) 2016-10-26
LT2841445T (lt) 2017-09-11
CO7170182A2 (es) 2015-01-28
HRP20171275T1 (hr) 2017-10-20
EP3444261A1 (en) 2019-02-20
KR20150003875A (ko) 2015-01-09
SG11201406868XA (en) 2014-11-27
CN104395332A (zh) 2015-03-04
TWI623548B (zh) 2018-05-11
ES2861393T3 (es) 2021-10-06
EA030468B1 (ru) 2018-08-31
DK2841445T3 (en) 2017-09-11
EA201491972A1 (ru) 2015-02-27
ME02926B (me) 2018-04-20
UA116209C2 (uk) 2018-02-26

Similar Documents

Publication Publication Date Title
RS61544B1 (sr) Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja
HRP20190318T1 (hr) Farmaceutski ili kozmetički pripravak za liječenje alopecije
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HK1212217A1 (en) Methods of treating alzheimers disease and pharmaceutical compositions thereof
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PL2729151T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
HK1200366A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11ss-17- 21-triol-3,20-dione derivatives 4--11-17-21--320-
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
DK3292875T3 (en) Compositions and methods for treating diseases
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
IL254289A0 (en) History of fatty acids and pharmaceutical preparations containing them for the treatment of schizophrenia
EP2789613A4 (en) 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE